| Literature DB >> 26282854 |
Wenjun Yan1, Jianchao Wei2, Xufang Deng3, Zixue Shi4, Zixiang Zhu5, Donghua Shao6, Beibei Li7, Shaohui Wang8, Guangzhi Tong9, Zhiyong Ma10.
Abstract
BACKGROUND: p53 is a tumor suppressor that contributes to the host immune response against viral infections in addition to its well-established protective role against cancer development. In response to influenza A virus (IAV) infection, p53 is activated and plays an essential role in inhibiting IAV replication. As a transcription factor, p53 regulates the expression of a range of downstream responsive genes either directly or indirectly in response to viral infection. We compared the expression profiles of immune-related genes between IAV-infected wild-type p53 (p53WT) and p53-deficient (p53KO) mice to gain an insight into the basis of p53-mediated antiviral response.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26282854 PMCID: PMC4539693 DOI: 10.1186/s12920-015-0127-8
Source DB: PubMed Journal: BMC Med Genomics ISSN: 1755-8794 Impact factor: 3.063
Mice groups assigned for microarray analysis
| Sampling 3 dpi | Sampling 6 dpi | ||
|---|---|---|---|
| PR8-infection | p53WT mice | 3a | 3 |
| p53KO mice | 3 | 3 | |
| Mock-infection | p53WT mice | 3 | 3 |
| p53KO mice | 3 | 3 |
dpi days post-infection
anumber of mice per group
Fig. 1Increased susceptibility of p53KO mice to PR8 infection. p53WT and p53KO mice (n = 10 per group) were intranasally inoculated with a sublethal dose of PR8 virus. Clinical signs and weight loss were assessed daily for 16 days. Lungs of infected mice were collected 3 and 6 dpi for analysis of viral loads. a Weight loss analysis in PR8-infected mice. Results are percentages of mean weight loss relative to initial weight. b The survival rates of PR8-infected mice. c Viral loads were determined by serial titration of lung homogenates in 10-day-old embryonated SPF chicken eggs. The EID50 was calculated. d The expression of viral hemagglutinin (HA) in the lungs of infected mice was determined by qRT-PCR. Values are means ± SE of at least 4 mice. *, p < 0.05 as assessed by the Student’s t-test; dpi, days post-infection
Number of significantly changed genes
| Regulation | p53WTa | p53WT vs p53KOb | ||
|---|---|---|---|---|
| 3 dpi | Up | Total genes | 964 | 508 |
| Immune-related genes | 275 | 94 | ||
| Down | Total genes | 1016 | 579 | |
| Immune-related genes | 236 | 135 | ||
| 6 dpi | Up | Total genes | 987 | 639 |
| Immune-related genes | 320 | 193 | ||
| Down | Total genes | 1258 | 861 | |
| Immune-related gens | 279 | 184 |
anumber of significantly changed genes in PR8-infected p53WT mice compared to mock-infected p53WT mice
bnumber of genes showing a significantly different expression between PR8-infected p53WT and p53KO mice
GO analysis of genes with attenuated expression in PR8-infected p53KO mice
| GO ID | Category | 3 dpi | 6 dpi | ||
|---|---|---|---|---|---|
| Number of genes | Representative genes | Number of genes | Representative genes | ||
| GO:0002684 | Positive regulation of immune system process | 5 |
| 18 |
|
| GO:0002682 | Regulation of immune system process | 8 |
| 24 |
|
| GO:0050900 | Leukocyte migration | 2 |
| 6 |
|
| GO:0045321 | Leukocyte activation | 7 |
| 20 |
|
| GO:0019882 | Antigen processing and presentation | 2 |
| 5 |
|
| GO:0001776 | Leukocyte homeostasis | 2 |
| 6 |
|
| GO:0002252 | Immune effecter process | 6 |
| 17 |
|
| GO:0002253 | Activation of immune response | 1 |
| 8 |
|
| GO:0002200 | Somatic diversification of immune receptors | 4 |
| 5 |
|
| GO:0002520 | Immune system development | 10 |
| 23 |
|
| GO:0006955 | Immune response | 13 |
| 47 |
|
GO analysis of genes significantly expressed in PR8-p53KO mice
| GO ID | Category | 3 dpi | 6 dpi | ||
|---|---|---|---|---|---|
| Number of genes | Representative genes | Number of genes | Representative genes | ||
| GO:0002683 | Negative regulation of immune system process | 1 |
| 0 | |
| GO:0002682 | Regulation of immune system process | 1 |
| 2 |
|
| GO:0031294 | Lymphocyte costimulation | 0 | 1 |
| |
| GO:0050900 | Leukocyte migration | 1 |
| 0 | |
| GO:0045321 | Leukocyte activation | 3 |
| 3 |
|
| GO:0002684 | Positive regulation of immune system process | 0 | 2 |
| |
| GO:0001776 | Leukocyte homeostasis | 0 | 1 |
| |
| GO:0002252 | Immune effector process | 3 |
| 0 | |
| GO:0002200 | Somatic diversification of immune receptors | 2 |
| 0 | |
| GO:0002520 | Immune system development | 6 |
| 7 |
|
| GO:0006955 | Immune response | 8 |
| 2 |
|
The expression of selected genes involved in interferon signaling pathway
| Gene symbol | Gene description | FCa (p53WT/p53KO) | |
|---|---|---|---|
| 3 dpi | 6 dpi | ||
|
| myxovirus (influenza virus) resistance 2 | 42.94/14.54b | 37.85/2.92b |
|
| 2'-5' oligoadenylate synthetase 2 | 14.75/12.43 | 13.20/3.06b |
|
| 2'-5' oligoadenylate synthetase 3 | 9.39/5.46 | 6.37/2.41b |
|
| eukaryotic translation initiation factor 2-alpha kinase 2 (PKR) | 4.98/4.71 | 4.53/1.60b |
|
| guanylate binding protein 1 | 2.95/1.59 | 2.51/1.12b |
|
| interferon induced transmembrane protein 1 | 2.50/2.32 | 2.58/1.24b |
|
| bone marrow stromal cell antigen 2 (Tetherin) | 3.41/2.22 | 2.96/1.02b |
|
| interferon-induced protein 44 | 4.59/2.82 | 2.98/1.09b |
|
| nicotinamide phosphoribosyltransferase | 2.59/2.52 | 3.62/1.78b |
|
| receptor transporter protein 4 | 7.16/7.68 | 9.56/3.91b |
|
| three prime repair exonuclease 1 | 6.72/11.63 | 8.32/2.98b |
|
| Fas death domain-associated protein | 6.27/6.39 | 7.79/1.59b |
|
| interferon gamma | 2.87/1.05b | 6.07/0.90b |
|
| interferon alpha B | 1.80/0.80b | 2.38/0.60b |
|
| signal transducer and activator of transcription 4 | 1.78/0.79 | 2.08/0.80b |
|
| signal transducer and activator of transcription 6 | 2.28/0.81b | 1.87/0.34 |
|
| interferon regulatory factor 5 | 2.10/3.99 | 2.89/1.27b |
|
| interferon regulatory factor 7 | 109.99/37.81b | 93.18/7.18b |
a FC fold change
bsignificant difference in gene expression between PR8-infected p53WT and p53KO mice
Fig. 2Detection of gene expression in PR8-infected mice by qRT-PCR. Lung samples were collected from PR8-infected mice 3 and 6 dpi and subjected to qRT-PCR for expression analysis of the indicated genes. FC, fold change. Results are means ± SE from 3 mice. *, p < 0.05 between PR8-infected p53WT and p53KO mice
The expression of selected cytokine and chemokine genes
| Gene symbol | Gene description | FCa (p53WT/p53KO) | |
|---|---|---|---|
| 3 dpi | 6 dpi | ||
|
| interleukin 1 beta | 2.30/3.71 | 2.85/0.93b |
|
| interleukin 6 | 3.27/2.79 | 2.52/0.95b |
|
| interleukin 7 | 0.65/0.47 | 0.34/0.83b |
|
| interleukin 15 | 2.64/1.72 | 2.05/0.67b |
|
| interleukin 16 | 4.93/0.15b | 1.20/0.99 |
|
| interleukin 3 receptor, alpha chain | 1.40/0.96 | 2.09/0.73b |
|
| Interleukin 10 receptor, alpha (Il10ra), mRNA | 3.04/3.16 | 4.14/1.21b |
|
| interleukin 17 receptor D | 0.48/0.41 | 0.07/0.45b |
|
| interleukin 17 receptor E | 0.60/0.81 | 0.45/1.55b |
|
| interleukin 20 receptor beta | 0.27/0.98b | 0.73/1.33 |
|
| chemokine (C-C motif) ligand 2 (MCP-1) | 11.83/130.82b | 22.32/9.89b |
|
| chemokine (C-C motif) ligand 3 (MIP-1α) | 7.90/11.23 | 9.62/1.90b |
|
| chemokine (C-C motif) ligand 4 (MIP-1β) | 18.00/15.62 | 16.91/2.03b |
|
| chemokine (C-C motif) ligand 7 | 42.24/79.44 | 52.60/8.94b |
|
| chemokine (C-C motif) ligand 11 | 1.15/3.31 | 8.15/3.12b |
|
| chemokine (C-C motif) ligand 19 | 2.55/4.33 | 3.68/1.83b |
|
| chemokine (C-C motif) ligand 25 | 0.27/1.09b | 0.58/1.53 |
|
| chemokine (C-X-C motif) ligand 1 | 21.07/6.71b | 8.63/0.30b |
|
| chemokine (C-X-C motif) ligand 9 | 39.58/120.08b | 40.63/17.95b |
|
| chemokine (C-X-C motif) ligand 10 (IP-10) | 161.21/220.07 | 114.77/19.91b |
|
| chemokine (C-X-C motif) ligand 13 | 2.48/10.71 | 7.60/1.71b |
|
| chemokine (C-X-C motif) ligand 14 | 1.38/1.93 | 2.10/0.96b |
|
| chemokine (C-C motif) receptor 6 | 0.56/0.47 | 0.28/1.04b |
|
| chemokine (C-C motif) receptor-like 2 | 2.89/2.26 | 2.35/0.82b |
|
| tumor necrosis factor | 9.43/34.25b | 8.90/1.06b |
|
| tumor necrosis factor receptor superfamily, member 10b | 0.46/2.18b | 1.26/1.80 |
|
| tumor necrosis factor (ligand) superfamily, member 11 | 0.27/0.08 | 5.88/1.81b |
|
| tumor necrosis factor receptor superfamily, member 8 | 5.86/1.08b | 0.88/0.01b |
|
| tumor necrosis factor receptor superfamily, member 18 | 2.55/2.13 | 3.86/1.43b |
a FC fold change
bsignificant difference in gene expression between PR8-infected p53WT and p53KO mice